- Home
- EHI vs ARCT Comparison
EHI vs ARCT Comparison
Compare EHI & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EHI | ARCT |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 181.2M | 198.1M |
| IPO Year | 2003 | 2019 |
Fundamental Metrics
Financial Performance| Metric | EHI | ARCT |
|---|---|---|
| Price | $5.80 | $5.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $24.11 |
| AVG Volume (30 Days) | 87.9K | ★ 564.0K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $82,031,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.80 | $5.74 |
| 52 Week High | $6.70 | $24.14 |
Technical Indicators
Market Signals| Indicator | EHI | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 30.49 | 26.97 |
| Support Level | N/A | N/A |
| Resistance Level | $6.03 | $7.98 |
| Average True Range (ATR) | 0.04 | 0.36 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 4.55 | 0.23 |
Price Performance
Historical ComparisonAbout EHI Western Asset Global High Income Fund Inc
Western Asset Global High Inc Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is high current income and total return by investing in a world-wide portfolio of securities. The fund invests in various sectors such as Consumer Discretionary, Financials, Energy, Communication energy, Industrials, materials, and others.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.